Biosimilar Drugs Offer Promise For Drug Price Savings, But Risks Remain

The issue of prescription drug prices continues to top the list of public concerns about health costs, and Congress and the administration are floating possible policy solutions. Solutions to this complex problem will be most effective if they are targeted and geared toward encouraging rather than undermining competition and innovation in the vibrant 21st...

Studies Show U.S. Patients Are Being Denied Access To Life-Saving Drugs

Decisions by health care authorities are impeding patients’ access to new medicines. That is a headline Americans expect to read about barriers to treatments in government-run health care systems that ration access to care, often to stay within their global spending budgets. But a study presented at the recent American College of Cardiology annual...

Far-Reaching Medicare Part B Changes Violate Separation Of Powers — And With CBO’s Blessing

Members of Congress expressed outrage at the Congressional Budget Office during a recent House hearing for assuming that sweeping, untested changes to Medicare will save $34 billion “even before you know what the project is,” Rep. Scott Garrett (R-NJ) said. “There is no cost-benefit analysis, there is no testing done, you don’t even know...

Competition in Medicare Advantage, Part D, and “Extra Help”/ Working together for seniors and taxpayers

Seniors are beginning to get fliers in the mail alerting them to the upcoming open season for enrollment in Medicare Advantage and Medicare Part D prescription drug plans.  Both programs rely on competition and consumer choice to increase options and hold down costs for seniors.  Open season begins October 15 for those planning to...